Scholarlink

<p>Introduction Pheochromocytoma (PCC) and paraganglioma (PG) research is limited due to rarity of disease. We utilized patient-derived tumor organoids (PTOs) to explore personalized treatment options for these patients. Tumors were obtained from patients with PCC and PG who underwent operative resection and processed to biofabricate PTOs utilizing a collagen-based hydrogel. Blood was also obtained from patients to generate immune-enhanced PTOs (iPTOs). Organoids underwent treatment with chemotherapy, immunotherapy, or tyrosine kinase inhibitors. Cell viability was determined using multiple assays. Significant treatments demonstrated viability &lt; 50% and p &lt; 0.05 compared to controls. Twelve PCC and 4 PG tumors were obtained from December 2020 – May 2023. Viable PTOs were generated in 15/16 (93.8%) tumors for drug studies. Sunitinib (10 µM) demonstrated significant treatment efficacy in 9/14 PTOs (64.3%) with average post-treatment viability of 28%. A commonly utilized clinical regimen of cyclophosphamide, vincristine, doxorubicin and dacarbazine (10 µM) demonstrated significant treatment effect in 3/7 treated PTOs (42.9%) with average post-treatment viability of 25.5%. Only 1/13 iPTOs (7.7%) demonstrated sensitivity to Ipilimumab/Nivolumab. Cultured PTOs produced measurable norepinephrine on ELISA. PTOs are a feasible platform to study PCC and PG and their response to systemic treatments on a personalized level. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Richard A. Erali,
  • Steven D. Forsythe,
  • Cecilia R. Schaaf,
  • Nicholas Edenhoffer,
  • William Meeker,
  • Cristian D. Valenzuela,
  • Wencheng Li,
  • Shay Soker,
  • Reese W. Randle,
  • Konstantinos I. Votanopoulos

摘要

Introduction Pheochromocytoma (PCC) and paraganglioma (PG) research is limited due to rarity of disease. We utilized patient-derived tumor organoids (PTOs) to explore personalized treatment options for these patients. Tumors were obtained from patients with PCC and PG who underwent operative resection and processed to biofabricate PTOs utilizing a collagen-based hydrogel. Blood was also obtained from patients to generate immune-enhanced PTOs (iPTOs). Organoids underwent treatment with chemotherapy, immunotherapy, or tyrosine kinase inhibitors. Cell viability was determined using multiple assays. Significant treatments demonstrated viability < 50% and p < 0.05 compared to controls. Twelve PCC and 4 PG tumors were obtained from December 2020 – May 2023. Viable PTOs were generated in 15/16 (93.8%) tumors for drug studies. Sunitinib (10 µM) demonstrated significant treatment efficacy in 9/14 PTOs (64.3%) with average post-treatment viability of 28%. A commonly utilized clinical regimen of cyclophosphamide, vincristine, doxorubicin and dacarbazine (10 µM) demonstrated significant treatment effect in 3/7 treated PTOs (42.9%) with average post-treatment viability of 25.5%. Only 1/13 iPTOs (7.7%) demonstrated sensitivity to Ipilimumab/Nivolumab. Cultured PTOs produced measurable norepinephrine on ELISA. PTOs are a feasible platform to study PCC and PG and their response to systemic treatments on a personalized level.